Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 653 matching trials from the live ClinicalTrials.gov search.
Conditions
Brain and Central Nervous System Tumors, Head and Neck Cancer, Lymphoma
Interventions
filgrastim, carmustine, cisplatin, cyclophosphamide, etoposide, thiotepa, adjuvant therapy, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Osteopenia, Osteoporosis, Osteonecrosis
Interventions
LLP2A-ALENDRONATE, Placebo
Drug
Lead sponsor
Nancy E. Lane, MD
Other
Eligibility
20 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Cypress, California • Walnut Creek, California • Duncansville, Pennsylvania + 1 more
Conditions
Primary Graft Failure
Interventions
FLT imaging and TK1 blood measurements
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Conditions
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions
Allogeneic hMSCs
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Genetic + 3 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Terminated Phase 1Phase 2 Interventional Results available

Maraviroc as GVHD Prophylaxis in Transplant Recipients

NCT02167451
Conditions
Diagnoses That Require Stem Cell Transplant, Graft Versus Host Disease (GVHD)
Interventions
Maraviroc
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Graft-Versus-Host Disease, GVHD, Undefined
Interventions
Photobiomodulation Therapy, Placebo sham device
Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
4 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Bethesda, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Conditions
Lymphoma
Interventions
filgrastim, recombinant human stem cell factor, cyclophosphamide, cytarabine, etoposide, melphalan, mitoxantrone hydrochloride, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis
Interventions
PDA001 (cenplacel-L)
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Birmingham, Alabama • Denver, Colorado • Cincinnati, Ohio + 1 more
Conditions
Leukemia
Interventions
therapeutic allogeneic lymphocytes, peripheral blood stem cell transplantation, radiation therapy
Biological · Procedure · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Conditions
Multiple Myeloma
Interventions
Linvoseltamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Denver, Colorado + 9 more
Conditions
CML, ALL, AML, Myelodysplasia, Lymphoma, Myeloproliferative Disorders
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 54 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
Filgrastim, Cladribine, Cyclosporine, Cytarabine (Ara-C), Fludarabine Phosphate, Idarubicin, Methylprednisolone, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
55 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
Interventions
Consolidative radiation therapy (cRT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 39 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Minneapolis, Minnesota
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, therapeutic allogeneic lymphocytes, thiotepa, allogeneic bone marrow transplantation, biological therapy, bone marrow ablation with stem cell support, bone marrow transplantation, chemotherapy, leukocyte therapy, non-specific immune-modulator therapy, peripheral blood lymphocyte therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lymphoma
Interventions
Bleomycin Sulfate (BLM), Filgrastim (G-CSF), Recombinant Interferon Alfa, Carmustine, Cisplatin (CDDP), Cyclophosphamide, Cytarabine (ARA-C), Etoposide (VP-16), Idarubicin, Ifosfamide, Leucovorin Calcium, Melphalan, Methotrexate, Methylprednisolone, mitoxantrone hydrochloride (DHAD), Vincristine Sulfate, Peripheral Blood Stem Cell Transplantation, Radiation Therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 59 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Parkinson's Disease, Parkinsonism
Interventions
Harvesting of neural stem cells
Procedure
Lead sponsor
NeuroGeneration
Industry
Eligibility
35 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Lymphoma
Interventions
filgrastim, busulfan, cyclophosphamide, etoposide, melphalan, autologous-autologous tandem hematopoietic stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, sorafenib tosylate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
204
States / cities
Scottsdale, Arizona • Fresno, California • Fort Collins, Colorado + 129 more
Conditions
Sickle Cell Disease, Stress, Pain
Interventions
Guided Relaxation video clip, Sickle Cell Disease Experience Discussion
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Hematopoietic Cell Transplantation
Interventions
Quadrivalent Inactivated Influenza Vaccine, Laboratory Biomarker Analysis, Trivalent Influenza Vaccine
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Nashville, Tennessee + 1 more
Conditions
Rotator Cuff Tears
Interventions
Adipose-derived stem cells, cortisone injection
Device
Lead sponsor
InGeneron, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Fargo, North Dakota • Sioux Falls, South Dakota